OCGN - Ocugen, Inc.
After hours:
| Previous close | 0.4583 |
| Open | 0.4600 |
| Bid | 0.4570 x 1200 |
| Ask | 0.4630 x 4000 |
| Day's range | 0.4500 - 0.4652 |
| 52-week range | 0.4400 - 3.1100 |
| Volume | |
| Avg. volume | 7,417,725 |
| Market cap | 117.958M |
| Beta (5Y monthly) | 3.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
- Motley Fool
Ocugen (OCGN) Q1 2023 Earnings Call Transcript
Joining me today are Ocugen's chairman, CEO and co-founder; Dr. Shankar Musunuri, who will provide a business update; and our chief financial officer and chief business officer, Quan Vu, who will provide a financial update. Earlier this morning, we issued a press release detailing business and operational highlights for the first quarter of 2023.
- Simply Wall St.
Ocugen, Inc. (NASDAQ:OCGN): Is Breakeven Near?
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s...
- Motley Fool
Why Ocugen Stock Eked Out a Win Today
Investors were pleased, if not overwhelmingly so, with Ocugen's (NASDAQ: OCGN) latest set of quarterly results on Tuesday. The biotech published its fourth-quarter and full-year figures that morning, in addition to providing a business update. Ocugen is a clinical-stage biotech that has no revenue at the moment.
- Motley Fool
Ocugen (OCGN) Q4 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more detail on our financial results. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.
- Motley Fool
More Likely to 5x First: Novavax vs. Ocugen
Biotech companies are ripe with innovation. The two stocks I'll talk about here -- Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) -- both have soared in recent years on optimism about potentially game-changing products. Novavax soared more than 2,700% in 2020 as investors bet on its investigational coronavirus vaccine.
- Motley Fool
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. Or has Ocugen left center stage for good? Let's consider one reason to buy Ocugen in 2023 -- and two reasons to sell.
- Motley Fool
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Teladoc Health (NYSE: TDOC) sank 74% last year -- and for one particular reason. The telemedicine giant reported two billion-dollar noncash goodwill impairment charges. Both were linked to the acquisition of chronic-care specialist Livongo.
- Motley Fool
3 of the Fastest-Growing Stocks on the Planet in 2023
It's why the Nasdaq Composite lost a third of its value last year. Despite this turmoil, some growth stocks are expected to deliver phenomenal sales growth in 2023 -- even as their share prices come under pressure. What follows are three of the fastest-growing stocks on the planet in 2023.
- Motley Fool
3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street
When the curtain closed on 2022, the ageless Dow Jones Industrial Average, widely followed S&P 500, and growth-dependent Nasdaq Composite, respectively finished lower by 9%, 19%, and 33%. It was, collectively, the worst performance for Wall Street in 14 years. This is why most analyst price targets point to upside in equities.
- Motley Fool
Why Shares of Ocugen Jumped Thursday
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) climbed as high as 14.2% on Thursday, to $1.29, shortly before noon. Ocugen focuses on gene and cell therapies and vaccines to treat retinal diseases, infectious diseases, and orthopedic conditions.
- Motley Fool
3 Stocks to Avoid Right Now
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
- Motley Fool
Why Ocugen Stock Wilted on Wednesday
Like meme stocks will do from time to time, Ocugen (NASDAQ: OCGN) on Wednesday saw a notable price drop a day after a surge. The company was hit by quite a severe price target cut from an analyst, a move that ruined the party after Tuesday's post-earnings run-up. Before market open Wednesday, Noble Capital's Robert LeBoyer made a nearly 40% chop to his Ocugen target.
- Motley Fool
Why Ocugen Stock Popped by 7% on Tuesday
A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.
- Motley Fool
Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman, CEO, and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more update on our financial results. Earlier this morning, we issued a press release detailing business activity for Q3 2022.
- Simply Wall St.
Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40%
If you want to know who really controls Ocugen, Inc. ( NASDAQ:OCGN ), then you'll have to look at the makeup of its...
- Motley Fool
3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street
Since the three major U.S. indexes achieved their all-time highs between the midpoint of November 2021 and the first week of January, each has fallen into a bear market, with peak declines ranging from 22% to 38%. Of course, optimism can vary quite significantly on Wall Street. What follows are three high-octane growth stocks that select analysts and pundits believe offer upside ranging from 357% to as much as 571%!
- Motley Fool
Wall Street Thinks This Top 100 Robinhood Stock Could Skyrocket by 217%
Vaccine maker Ocugen (NASDAQ: OCGN) has had a tumultuous past 18 months on the stock market. The company's shares soared as it sought to make good on its intentions to enter the COVID-19 vaccine space, but with the delays it has encountered in this area, investors have largely given up.
- Motley Fool
Why Ocugen Stock Topped the Market Today
Although it hasn't been the most popular coronavirus stock, Ocugen (NASDAQ: OCGN) clearly found some new fans on Thursday. In a one-two punch, Ocugen has appointed a new chief medical officer and chief scientific officer. The former is Robert Hopkins, a physician with over 20 years in both the public and private sectors of the healthcare industry.
- Motley Fool
Why Ocugen Stock Is Racing Higher Today
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) are on fire today. Mizuho's analyst noted that Ocugen's shares are only currently being valued at the commercial potential of its COVID-19 vaccine known as Covaxin. Ocugen is co-commercializing the vaccine in North America with its developer Bharat Biotech of India.
- Motley Fool
Here's How This Beaten-Down Stock Could 10X by 2024
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
- Motley Fool
1 Robinhood Stock to Avoid Right Now
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
- Motley Fool
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.
- Zacks
Ocugen Q2 Preview: Rebound Quarter Inbound?
Ocugen shares have struggled over the last year, declining more than 60% in value and vastly underperforming the S&P 500.
- Simply Wall St.
Analysts Expect Breakeven For Ocugen, Inc. (NASDAQ:OCGN) Before Long
We feel now is a pretty good time to analyse Ocugen, Inc.'s ( NASDAQ:OCGN ) business as it appears the company may be...
